Synthesis and physicochemical characterization of a new gadolinium chelate:: The liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA

被引:89
作者
Schmitt-Willich, H [1 ]
Brehm, M [1 ]
Ewers, CLJ [1 ]
Michl, G [1 ]
Müller-Fahrnow, A [1 ]
Petrov, O [1 ]
Platzek, J [1 ]
Radüchel, B [1 ]
Sülzle, D [1 ]
机构
[1] Schering AG, Res Labs, D-13342 Berlin, Germany
关键词
D O I
10.1021/ic981072i
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
A convenient synthesis of disodium S-[4-(4-ethoxybenzyl)-3,6,9-tris[(carboxy-kappa O)methyl]-3,6,9-triazaundecandioato)(5-)-kappa(3)N(3),N-6,N-9,kappa(2)O(1),O-11]gadolinate(2-) (Gd-EOB-DTPA), 1, is reported. This water-soluble complex is presently undergoing phase III clinical trials as a liver-specific contrast agent for magnetic resonance imaging (MRI). The thermodynamic complex stability constant of 1 and the acid dissociation constants of the ligand have been determined as well as the stability constant of the calcium complex Ca-EOB-DTPA (2), which is used as an additive in the pharmaceutical formulation of the contrast agent. The solid-state structure of the ligand S-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid (H5EOB-DTPA), 3, has been elucidated in a single crystal X-ray diffraction study. Additionally, HPLC evidence is given that the enantiomerically pure ligand forms two diastereomeric gadolinium complexes in a 65:35 ratio. The kinetics of isomerization of the isolated diastereomers-as dependent on pH and temperature-has been investigated, and thus, the activation energy for the interconversion of these isomers has been estimated to be 75.3 kJ mol(-1). Finally, the structures of the two components of 1 are discussed in terms of four possible diastereomers.
引用
收藏
页码:1134 / 1144
页数:11
相关论文
共 48 条
[1]   A novel compound in the lanthanide(III) DOTA series. X-ray crystal and molecular structure of the complex Na[La(DOTA)La(HDOTA)]center dot 10H(2)O [J].
Aime, S ;
Barge, A ;
Benetollo, F ;
Bombieri, G ;
Botta, M ;
Uggeri, F .
INORGANIC CHEMISTRY, 1997, 36 (19) :4287-4289
[2]   Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA [J].
Aime, S ;
Barge, A ;
Botta, M ;
Fasano, M ;
Ayala, JD ;
Bombieri, G .
INORGANICA CHIMICA ACTA, 1996, 246 (1-2) :423-429
[3]   NMR-STUDY OF SOLUTION STRUCTURES AND DYNAMICS OF LANTHANIDE(III) COMPLEXES OF DOTA [J].
AIME, S ;
BOTTA, M ;
ERMONDI, G .
INORGANIC CHEMISTRY, 1992, 31 (21) :4291-4299
[4]  
[Anonymous], 1974, Critical Stability Constants
[5]  
[Anonymous], 1992, DETERMINATION USE ST
[6]   Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: A European perspective [J].
Aslanian, V ;
Lemaignen, H ;
Bunouf, P ;
Svaland, MG ;
Borseth, A ;
Lundby, B .
NEURORADIOLOGY, 1996, 38 (06) :537-541
[7]   Certain amino derivatives of lauric acid [J].
Birosel, DM .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1931, 53 (02) :3039-3041
[8]  
BRADY TJ, 1996, ENCY NUCL MAGNETIC R, V3, P1432
[9]  
BRASCH RC, 1992, RADIOLOGY, V183, P1
[10]   BACKBONE-SUBSTITUTED DTPA LIGANDS FOR Y-90 RADIOIMMUNOTHERAPY [J].
BRECHBIEL, MW ;
GANSOW, OA .
BIOCONJUGATE CHEMISTRY, 1991, 2 (03) :187-194